概览
Meeting: September 9 – September 11
DIA’s 2026 Latin America Annual Meeting offers unparalleled opportunities for networking and knowledge sharing with key stakeholders to advance and implement life sciences R&D initiatives in Latin America and the Caribbean. This year, session tracks on Regulatory/Clinical and Safety and Pharmacovigilance expand the scope of the meeting, with cross-track sessions facilitating discussions on key connection points across these areas to promote collaboration and synergy within organizations.
In addition, interactive workshops will be introduced to provide hands-on discussions and practical learning experiences, fostering deeper engagement and the exchange of real-world insights among participants. Medical devices will also serve as an overarching topic throughout the agenda, integrated across sessions to address emerging regulatory, clinical, and safety considerations.
Join the conversation on multi-regional cooperation, global harmonization and reliance, lessons learned, and best practices. Don’t miss the chance to be part of this pivotal event, where innovation and cooperation come together to shape the future of healthcare in the region.
The primary language is Spanish, however simultaneous interpretation in English and Portuguese will be available during this meeting.
While we develop our 2026 Agenda, please take a moment to review our 2025 FINAL PROGRAM!
Participant Testimonials
The DIA event was everything I need and more, every one of the different sessions was really well organized and coherent. The speakers and the different panelists were always experts in their areas and this stimulates the different panel discussions. Moreover, the different activities that were organized for regulators or other stakeholders were an amazing opportunity to have contact and share experiences with people that are doing the same activities and have the same problems or challenges. I will recommend everyone to attend to the next event. - José Crisóstomo Landeros, Head of Marketing Authorization for Biological Products, Public Health Institute Chile (ISP)
The DIA LAAM event was a truly transformative experience, offering profound insights -especially during the patient-centric sessions. It provides an essential forum for professionals from diverse backgrounds to exchange knowledge in a collaborative environment. For colleagues in the pharmaceutical industry and at health authorities, I believe attending is a critical step toward achieving greater regulatory reliance and convergence. This is how we build a future of healthcare defined by transparency, close collaboration, and equity across nations. - Erika Hannibal, Senior Regulatory Group Director, LatAm Area Lead, Roche International Ltd.
I had an outstanding experience at the DIA meeting, where the energy of innovation and collaboration was truly inspiring. The sessions offered a perfect blend of cutting-edge insights, practical solutions, and thought-provoking discussions that sparked new ideas for advancing patient care. Beyond the rich content, the opportunity to connect with professionals from diverse backgrounds created a vibrant exchange of knowledge and perspectives. The atmosphere was both professional and welcoming, making it easy to engage in meaningful conversations and build valuable relationships. Overall, the conference left me motivated, better informed, and excited to bring these learnings back to my work. - Abraham Mota, Regulatory Affairs Manager, Eli Lilly and Company
项目委员会
-
Juan Asbun Pharmacovigilance and Patient Safety Regional Lead
Takeda México, S.A. De C.V., Mexico -
Augusto Bencke Geyer, MSc Health Regulatory Expert, International Affairs Office
ANVISA, Brazil -
Daniela Bravo, DrSc, MBA, MSc Regulatory Policy and Intelligence Latam Associate Director
AbbVie, Brazil -
Arthur Bueno, PharmD, MBA Country Safety Head Back-Up
Sanofi Brazil, Brazil -
Martin Cabrera Carchio, MA International Relations Advisor
ANMAT Ministry of Health, Argentina -
Margarita Contreras Olvera Official of International Affairs Office
COFEPRIS, Mexico -
Priscila De Lara Fagundes Esteves, RPh Director Regulatory Affairs
PPD Clinical Research Services, Thermo Fisher Scientific, Brazil -
Flavia Firmino Ribeiro, PharmD Regulatory Policy Lead - Latin America
Eli Lilly and Company, Brazil -
Rivelino Flores, MSc Director, Regulatory Affairs & Innovation
CANIFARMA, Mexico -
Cinthya Galicia Sr. Manager Country Safety Lead
Pfizer, Mexico -
Ana Paula Goncalvez Senior Director, Patient Safety Intercontinental
Bristol-Myers Squibb , Brazil -
Diana Gonzalez, MD, MBA Colombia PSL & PV Policy Lead Latam
Roche, Colombia -
Lawrence Liberti, PhD, RAC Director, D.K. Kim International Center for Regulatory Science
The Kim Center/ USC DRQS, United States -
Monica Lizano, MD, MBA Global Director, Clinical Quality Management
Merck Chile, Chile -
Josefina Mendoza PV Alliance LATAM, Head of PV CAMEX, LRP-PV CAM. Global Drug Safety
Grünenthal LATAM, Panama -
Monica Darinka Ramirez Quiroz Drug Safety Director
MSD Mexico, Mexico -
Maria Antonieta Roman, MPharm Head Regulatory Policy LaCan
Novartis, Mexico -
Begoña Sagastuy Advisor, Regulatory System Strengthening
Pan American Health Organization (PAHO), United States -
Diego Alexander Salas, LLM Regulatory Affairs Director
Federación Latinoamericana de la Industria Farmacéutica, A.C., Mexico -
Jorge Tanaka Director of Clinical Research
AMIIF Asociación Mexicana de Industrias de Investigación Farmacéutica, A.C., Mexico -
Sara Glenn Tylosky, MBA Chief Executive Officer
Farmacon Global, United States -
Lina Valero, MD, MBA, MSc Regional PV Head LATAM
Opella Healthcare, Colombia -
Maritza Villanueva Perez
COFEPRIS, Mexico -
Cesar Vinces Advisor, Regulatory Innovation
Nuvara, LLC, United States -
Vesa Vuniqi, MS International Relations Specialist, Latin America Office
FDA, United States
